Biotalys Announces Intention to Strategically Refocus its Activities to Prioritize Lead Assets and Reduce Annual Cash Burn

Core Insights - Biotalys is undergoing a strategic refocus to concentrate resources on its highest-priority programs and streamline operations [1][2] - The company aims to reduce total cash burn by €20 million until the end of 2028 compared to its current operating structure [2] - The focus will be on advancing its lead biofungicide assets, particularly EVOCA NG and BioFun-6, while maintaining partnerships for other programs [3] Organizational Changes - Biotalys plans to right-size its organizational structure and suspend early-stage activities to lower operating expenses [2] - The workforce will be reduced by 30 employees to align with the new strategy [4] - The company confirms its cash runway extends into May 2026 and is exploring financing options to support its refocused portfolio [4][9] Product Development - EVOCA NG is expected to be Biotalys' first commercial biofungicide, with a planned launch in the USA in 2029 and in Europe in 2030, targeting a market worth over USD 1.1 billion [5] - The U.S. EPA has approved the first-generation version of EVOCA, facilitating a shorter regulatory review process for EVOCA NG [6] Company Background - Biotalys is an AgTech company focused on developing protein-based biocontrol solutions for sustainable crop protection [7] - The company was founded in 2013 as a spin-off from the VIB and is based in Ghent, Belgium [7] - Biotalys employs an average of 59 employees as of 2025 [11]